NCT01967381View on ClinicalTrials.gov

Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
Methamphetamine AbuseMethamphetamine Dependence
Interventions
DRUG

Methamphetamine (Desoxyn®)

The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.

Trial Locations (1)

40536

University of Kentucky Medical Center, Lexington

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

University of Kentucky

OTHER

NCT01967381 - Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse | Biotech Hunter | Biotech Hunter